Research programme: intranasal allergy vaccine - ID Biomedical
Alternative Names: Intranasal allergy vaccine research programme - ID BiomedicalLatest Information Update: 25 Feb 2008
At a glance
- Originator ID Biomedical Corporation
- Class Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 25 Feb 2008 No development reported - Preclinical for Allergy (Intranasal)
- 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
- 06 Nov 2001 Preclinical development for Allergy (Intranasal)